Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remestemcel-L for COVID-19 ARDS
NCT04371393Phase 3Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 3 trial of Provacel in COVID-19-associated acute respiratory distress syndrome (CARDS), sponsored by Icahn School of Medicine at Mount Sinai. Started Apr 2020; status: terminated.
02
Drugs
Provacel
03
Conditions
COVID-19-associated acute respiratory distress syndrome (CARDS)
Beyond the preview
Go deeper on NCT04371393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371393.